Search by ticker code:
Generic filters

Search by ticker code:
Generic filters

Search by ticker code:
Generic filters

Is Short-Term Chinese Pain Worth Long-Term Gain For CSL’s (ASX:CSL) Share Price?

Healthcare giant CSL Limited (ASX: CSL) has outlined the effects of transitioning to its own distributor model in China.

Founded in the late 1900s as the Commonwealth Serum Laboratories, ‘CSL’ was sold by the Australian Government to shareholders via the ASX in 1994 at only $2.30 a pop. It used the money to double its size through an international acquisition. CSL is now a global leader in blood plasma vaccines (think: the flu, snake bite anti-venoms, etc.), providing relief for potentially life-threatening medical conditions.

CSL’s Chinese Update

Earlier this year CSL advised that it would be transitioning to its own ‘Good Supply Practice (GSP) License’ in China in FY20, which would enable the company to own and sell products in the domestic Chinese market.

However, this will lead to a number of one-off effects in FY20.

The transition will lead to lower reported albumin sales of approximately $340 million to $370 million. CSL also said that the profit effect will be in line with historical CSL Behring margins. Third, it will have a “more modest” impact on cashflow as CSL continues to collect outstanding receivables from existing distributors. The new model will improve cash collection.

Annual sales of albumin in China are expected to return to a more “normalised” level in FY21 after this change.

CSL has been importing albumin into China for more than 30 years and is now the largest supplier of imported human albumin. In FY18 CSL’s albumin sales in this market were over $500 million.

It takes months for CSL’s product to get from the manufacturing facilities in the USA and Europe to get to China, quality release by Chinese authority, maintenance of contingency stock and distribution to hospitals and pharmacies. CSL will recognise its sales at a later stage in the cycle.

Is CSL A Buy?

The direct trading model will allow CSL to increase its participation in the value chain, remove the reliance on third parties and let CSL work directly with clinicians. There are a lot of benefits to this transition.

The FY20 accounts might look a bit lighter than normal, which is why the CSL share price is down more than 3% in early trade. But, it’s probably good for the long term. CSL is a great business, but I think it will probably trade at a price cheaper than today over the next year or so.

Until then, I’d rather think about buying the reliable ASX shares in the free report below for my portfolio.

[ls_content_block id=”14945″ para=”paragraphs”]

[ls_content_block id=”18380″ para=”paragraphs”]

$50,000 per year in passive income from shares? Yes, please!

With interest rates UP, now could be one of the best times to start earning passive income from a portfolio. Imagine earning 4%, 5% — or more — in dividend passive income from the best shares, LICs, or ETFs… it’s like magic.

So how do the best investors do it?

Chief Investment Officer Owen Rask has just released his brand new passive income report. Owen has outlined 10 of his favourite ETFs and shares to watch, his rules for passive income investing, why he would buy ETFs before LICs and more.

You can INSTANTLY access Owen’s report for FREE by CLICKING HERE NOW and creating a 100% FREE Rask Account.

(Psst. By creating a free Rask account, you’ll also get access to 15+ online courses, 1,000+ podcasts, invites to events, a weekly value investing newsletter and more!)

Unsubscribe anytime. Read our TermsFinancial Services GuidePrivacy Policy. We’ll never sell your email address. Our company is Australian owned.

Information warning: The information on this website is published by The Rask Group Pty Ltd (ABN: 36 622 810 995) is limited to factual information or (at most) general financial advice only. That means, the information and advice does not take into account your objectives, financial situation or needs. It is not specific to you, your needs, goals or objectives. Because of that, you should consider if the advice is appropriate to you and your needs, before acting on the information. If you don’t know what your needs are, you should consult a trusted and licensed financial adviser who can provide you with personal financial product advice. In addition, you should obtain and read the product disclosure statement (PDS) before making a decision to acquire a financial product. Please read our Terms and Conditions and Financial Services Guide before using this website. The Rask Group Pty Ltd is a Corporate Authorised Representative (#1280930) of AFSL #383169.

Skip to content